Cipla gets 12 USFDA observations for Goa facility
"The United States Food and Drug Administration (USFDA) conducted a cGMP inspection at our Goa manufacturing facility from September 16-27, 2019," Cipla said in a filing.
New Delhi: Drugmaker Cipla announced that the US health regulator has completed the inspection of its manufacturing facility at Goa with 12 observations.
The inspection of the facility was conducted from September 16 2019, till September 27 2019.
"The United States Food and Drug Administration (USFDA) conducted a cGMP inspection at our Goa manufacturing facility from September 16-27, 2019," Cipla said in a filing.
"The inspection ended with 12 observations, none of which are related to data integrity. The Company will respond to the agency within the stipulated timeline," the company added.
Read Also: Cipla launches skin treatment Daptomycin Injection in the US
Headquartered in Mumbai, Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control and depression; other medical conditions.
Read Also: Cipla employee settles a case with SEBI, pays Rs 3 lakh
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd